Events

Apollo Therapeutics is pleased to share that Malcolm Begg Ph.D. FBPhS, VP, Global Program Leader, will be presenting at the Vaccines R&D Conference in Boston next week (5–7 November).

Malcolm will present the latest preclinical data on APL-10456, the first complete cross-strain rhinovirus vaccine candidate for prevention of exacerbations in COPD/asthma. The technical package supporting APL-10456 progression into clinical development will be presented on Thursday November 6, 11:05–11:30am EST.